KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).

Germán Áñez, Alice McGarry, Wayne Woo, Karen L Kotloff, Cynthia L Gay, Mingzhu Zhu, Shane Cloney-Clark, Joy Nelson, Haoua Dunbar, Miranda R Cai, Iksung Cho, Zhaohui Cai, Raj Kalkeri, Joyce S Plested, Nita Patel, Katherine Smith, Anthony M Marchese, Gregory M Glenn, Raburn M Mallory, Lisa M Dunkle, 2019CoVn-301 Study Investigators

Vaccine 61 127362

PMID40479932
PMCIDPMC12309408
DOI10.1016/j.vaccine.2025.127362
发表日期2025-06-06
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:ROC 图;Figure 3:ROC 图;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUND: NVX-CoV2373, a recombinant SARS-CoV-2 spike (rS) protein vaccine with Matrix-M® adjuvant, has been authorized for use in adults and adolescents. PREVENT-19 (NCT04611802/2019nCoV-301), a pivotal phase 3, randomized, placebo-controlled trial demonstrated robust efficacy of a primary, 2-dose series of NVX-CoV2373 against COVID-19. METHODS: Protocol expansions to PREVENT-19 included enrollment of adolescents (aged 12 to <18 years) and administration of 3rd and 4th doses of NVX-CoV2373 to adults and adolescents. Participants randomized 2:1 received NVX-CoV2373 or placebo 21 days apart; 3rd and 4th doses were administered ≥6 months after the preceding dose. Secondary and additional assessments included post-3rd- and 4th-dose immune responses (neutralizing antibody [nAb], anti-rS IgG, human angiotensin-converting enzyme-2-receptor binding inhibition [hACE2-RBI]) and response durability (post-3rd dose) to ancestral virus; cross-reactivity to Omicron subvariants; safety; and reactogenicity. RESULTS: Immune responses were observed against ancestral virus after two doses of NVX-CoV2373 but not after placebo. In both adults and adolescents, additional doses of NVX-CoV2373 increased nAb titers, anti-rS IgG levels, and hACE2-RBI; durable responses were recorded 8 months post 3rd dose. nAb responses post 3rd dose were noninferior to those post primary series. Cross-reactivity to BA.5 and BQ.1.1 variants was also observed, with anti-rS IgG levels post 3rd or 4th dose exceeding previously reported correlates of protection. Additional doses of NVX-CoV2373 were well tolerated, with no new safety signals. CONCLUSIONS: NVX-CoV2373 elicited robust and durable humoral immune responses to ancestral SARS-CoV-2 as a 3rd and 4th dose after the primary series in adults and adolescents. Cross-reactivity to relevant variants provides insight into potential protection against antigenically related, but shifted, viral strains. Additional doses of NVX-CoV2373 were well tolerated with no new safety signals. These results support the utility of this vaccine platform and continued updates, based on currently circulating strains, to help effectively combat SARS-CoV-2 infection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. CONSORT diagram. Participant enrollment and disposition for adult and adolescent populations. (A) Primary series and crossover. (B) Dose expansion. Part of this figure was adapted from Añez G, et al. JAMA Netw Open . 2023;6(4):e239135. *Other reasons include receipt of another COVID-19 vaccine, noncompliance, investigator decision, incarceration, and pregnancy. † Participants could have more than one reason for exclusion. ‡ Participants with an immunogenicity sample after the 3rd dose were a combination of those who received 2 doses of NVX-CoV2373 in the initial series and those who received 2 doses during blinded crossover. § Three participants were excluded from the adult 4 th -dose safety analysis set due to receipt of an external COVID-19 vaccine or an extra dose of NVX-CoV2373; three participants excluded from the adolescent PP-IMM set who received only 3 doses of NVX-CoV2373 are included in the 4 th -dose safety analysis set.
非 KM Figure
Figure 2Figure 2.. nAb responses against the ancestral strain in PP-IMM analysis sets. A) Adults. B) Adolescents. C) Noninferiority comparison of nAb responses after the primary series and 3rd dose. Baseline/pre-dose are defined as the last available assessment prior to administration of trial vaccine for the 1st, 3rd, or 4th dose. Post dose is 14 days (Day 35) after the primary series and 28 days after the 3rd or 4th dose. GMFR was calculated based on titer comparison of respective post vaccination and baseline samples for each group. SCR was calculated based on the number of participants with a ≥4-fold increase in antibody concentration from baseline divided by the number of participants with a sample collected at the designated post vaccination time. GMFR and SCR values with 95% CIs are noted. To establish noninferiority, the following criteria were to be met: lower bound (LB) of two-sided 95% CI for the ratio of GMTs (GMTthird/GMTprimary) >1.0; and LB of the two-sided 95% CI for the difference of SCR (GMTthird − GMTprimary) > −10%. Responses are compared 14 days (Day 35) after the primary series and 28 days after the 3rd dose. Criteria boundaries for 95% CI are marked with a dashed vertical line. GMT, geometric mean titer; LB, lower bound; nAb, neutralizing antibody; SCR, seroconversion rate.
非 KM Figure
Figure 3Figure 3.. Immunogenicity in an adult PP-IMM subset against the ancestral strain, BA.5, and BQ.1.1 before and after the primary series, 3 rd dose, and 4 th dose. A) Pseudovirus neutralization assay (n=15 participants for each timepoint and strain). B) Anti-rS IgG responses regardless of baseline SARS-CoV-2 serostatus (n=40 participants for each timepoint and strain, other than for 38 participants for 28 days after the 4 th dose). C) Anti-rS IgG responses by baseline SARS-CoV-2 serostatus (n=20 participants for each timepoint and strain, other than for 18 participants for 28 days after the 4 th dose). Fold differences compared with the ancestral strain for each series are shown in brackets. GMFR are comparing GMTs from samples collected on the day of dosing (before vaccination) with samples collected 28 days after that same dose. CoP values in (B) were determined for the ancestral strain based on Day 35 anti-rS IgG levels with protection 56 days later (Fong et al 2022). CoP, correlate of protection; GMFR, geometric mean fold rise; GMT, geometric mean titer; SCR, seroconversion rate.
非 KM Figure
Figure 4Figure 4.. Reactogenicity within 7 days of each study dose. Solicited (A) local and (B) systemic treatment-emergent adverse events were collected in adult (top) and adolescent (bottom) participants in the safety analysis sets with at least one eDiary entry. Note: There are no placebo reactogenicity data beyond the primary series as subsequent doses of placebo were not administered.
非 KM Figure